Platé, M;
Guillotin, D;
Chambers, RC;
(2020)
The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis.
European Respiratory Review
, 29
(157)
, Article 200269. 10.1183/16000617.0269-2020.
Preview |
Text
200269.full.pdf - Published Version Download (459kB) | Preview |
Abstract
Idiopathic pulmonary fibrosis (IPF) is characterised by the progressive deposition of excessive extracellular matrix proteins within the lung parenchyma and represents the most rapidly progressive and fatal of all fibrotic conditions. Current anti-fibrotic drugs approved for the treatment of IPF fail to halt disease progression and have significant side-effect profiles. Therefore, there remains a pressing need to develop novel therapeutic strategies for IPF. Mammalian target of rapamycin (mTOR) forms the catalytic subunit of two complexes, mTORC1 and mTORC2. mTORC1 acts as critical cellular sensor which integrates intracellular and extracellular signals to reciprocally regulate a variety of anabolic and catabolic processes. The emerging evidence for a critical role for mTORC1 in influencing extracellular matrix production, metabolism, autophagy and senescence in the setting of IPF highlights this axis as a novel therapeutic target with the potential to impact multiple IPF pathomechanisms.
Archive Staff Only
 |
View Item |
